title: Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib.
abstract: OBJECTIVE
  To study the functional status and health-related quality of life (HRQOL) of patients with rheumatoid arthritis (RA) after treatment with celecoxib, compared with placebo and naproxen.
  
  
  METHODS
  This was a prospective, randomized, double-blind, parallel group trial conducted at 79 sites in the United States and Canada over a 12-week treatment period. Patients were randomly assigned to 5 groups: placebo, 100 mg twice a day of celecoxib, 200 mg twice a day of celecoxib, 400 mg twice a day of celecoxib, and 500 mg twice a day of naproxen. The Health Assessment Questionnaire (HAQ) disability index was used to measure functional status. The Medical Outcomes Study Short Form 36 (SF-36) was used to measure general HRQOL.
  
  
  RESULTS
  Enrollees were 1,149 patients with diagnosed and active RA. At the end of the treatment period, patients in the 4 active treatment groups had significant improvement in both functional status and overall HRQOL in comparison with the placebo group. Patients in the twice-daily 100 mg celecoxib group significantly differed from placebo at weeks 2 and 6 on HAQ scores and at week 12 on 5 domains and both summary scores of the SF-36. Patients treated with twice-daily 200 mg celecoxib had significantly better functional status than placebo at all times of testing with the HAQ, and also had significantly better function than those treated with naproxen after 2 and 12 weeks of treatment. Patients in the twice-daily 200 mg and 400 mg celecoxib groups showed similar improvement in HRQOL as determined by the 8 domain scores and 2 summary scores of the SF-36.
  
  
  CONCLUSIONS
  Celecoxib was better than placebo and comparable with naproxen in improving functional status and overall HRQOL among RA patients.
authors.affiliation: Global Health Outcomes, G.D. Searle & CO., 5200 Old Orchard Road, Skokie, IL 60077, USA.
authors.forename: S Z
authors.initials: SZ
authors.lastname: Zhao
authors.forename: J I
authors.initials: JI
authors.lastname: Fiechtner
authors.forename: E A
authors.initials: EA
authors.lastname: Tindall
authors.forename: S D
authors.initials: SD
authors.lastname: Dedhiya
authors.forename: W W
authors.initials: WW
authors.lastname: Zhao
authors.forename: J T
authors.initials: JT
authors.lastname: Osterhaus
authors.forename: S S
authors.initials: SS
authors.lastname: Yu
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000523:psychology*; D002170:Canada; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000627:therapeutic use; D011446:Prospective Studies; D011720:Pyrazoles; D011788:Quality of Life; D013449:Sulfonamides / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014481:United States
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D009288:Naproxen; D000068579:Celecoxib